IL9 and asthma: Moreover, in two randomized phase 2a trials carried out in subjects with mild-to-moderate asthma, the humanized anti-IL-9 monoclonal antibody MEDI-528 exhibited an acceptable safety profile and also evoked a trend toward improvement in asthma symptom scores and disease exacerbation rates [83].